Biomerica, Inc. (NASDAQ:BMRA), (the "Company") a global provider of advanced medical products is pleased to announce advancements in the roll out of the inFoods IBS product.
Expansion Into New Offices and Physician Engagement:
Biomerica has expanded its reach with adoption by new offices in targeted regions, including the Southeast, Northeast and Midwest. The Company's new salesforce has activated over 30 new Gastrointestinal (GI) physician groups, each with multiple GI physicians, and these new practices have begun recommending the Company's revolutionary inFoods IBS Product to their IBS patients. Furthermore, the average increase in the number of physicians prescribing inFoods more than doubled each quarter over the past 12 months, reflecting growing adoption and trust within the GI medical community.
The Company is also in discussions with large non-GI physician groups for utilization of the inFoods IBS test. This advances the strategic effort to expand to non-GI physicians to provide cutting-edge non-pharmaceutical care options for individuals grappling with chronic IBS conditions.
This continued expansion demonstrates growing recognition and adoption of the inFoods IBS test in the medical community, broadening Biomerica's influence in providing innovative solutions for irritable bowel syndrome (IBS) while positioning the Company for product revenue growth over the coming quarters.